Betagenon AB and Baltic Bio AB have entered into an agreement to share profits from sale of rights belonging to Baltic Bio AB, including AMPK activator O304. Betagenon/Baltic Bio is now actively seeking partners for the further clinical development of O304 as a treatment for peripheral arterial disease, fatty liver disease (NASH), type 2 diabetes, diabetic complications, inflammatory disorders, and certain types of cancers.

Your name (required)

Your e-mail (required)


Your message